JP2016525502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525502A5 JP2016525502A5 JP2016519574A JP2016519574A JP2016525502A5 JP 2016525502 A5 JP2016525502 A5 JP 2016525502A5 JP 2016519574 A JP2016519574 A JP 2016519574A JP 2016519574 A JP2016519574 A JP 2016519574A JP 2016525502 A5 JP2016525502 A5 JP 2016525502A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 102000004965 antibodies Human genes 0.000 claims 11
- 108090001123 antibodies Proteins 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 6
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims 4
- 208000005613 Tauopathy Diseases 0.000 claims 4
- 201000002242 tauopathy Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000002569 neurons Anatomy 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 210000004897 N-terminal region Anatomy 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Claims (16)
- 個体におけるタウオパチーを処置するための医薬組成物であって、
Tauポリペプチドのアミノ末端(N末端)領域内のエピトープに特異的に結合するヒト化抗Tau抗体を含み;
該個体において、脳脊髄液(CSF)におけるAβ40および/またはAβ42の量、あるいはニューロンからのAβ40および/またはAβ42の分泌における減少をもたらす、医薬組成物。 - 個体におけるタウオパチーを処置するための医薬組成物であって、
Tauポリペプチドのアミノ末端(N末端)領域内のエピトープに特異的に結合するヒト化抗Tau抗体を含み、ここで、エピトープは、Tauポリペプチドのアミノ酸15−24内にあり;
該個体において、CSFにおけるAβ 40 および/またはAβ 42 の量、あるいはニューロンからのAβ 40 および/またはAβ 42 の分泌における減少をもたらす、医薬組成物。 - エピトープが線形エピトープである、請求項1に記載の医薬組成物。
- エピトープが、Tauポリペプチドのアミノ酸1−25または15−44内にある、請求項1または3に記載の医薬組成物。
- エピトープが、Tauポリペプチドのアミノ酸15−24内にある、請求項1または3に記載の医薬組成物。
- 個体におけるタウオパチーを処置するための医薬組成物であって、
a)TauポリペプチドのN末端領域内のエピトープへの結合を、
(i)配列番号1のアミノ酸配列を含むV L CDR1、
(ii)配列番号2のアミノ酸配列を含むV L CDR2、
(iii)配列番号3のアミノ酸配列を含むV L CDR3、
(iv)配列番号4のアミノ酸配列を含むV H CDR1、
(v)配列番号5のアミノ酸配列を含むV H CDR2、および
(vi)配列番号6のアミノ酸配列を含むV H CDR3、
または
(i)配列番号7のアミノ酸配列を含むV L CDR1、
(ii)配列番号8のアミノ酸配列を含むV L CDR2、
(iii)配列番号9のアミノ酸配列を含むV L CDR3、
(iv)配列番号10のアミノ酸配列を含むV H CDR1、
(v)配列番号11のアミノ酸配列を含むV H CDR2、および
(vi)配列番号12のアミノ酸配列を含むV H CDR3
を含む参照抗体と競合する、ヒト化軽鎖フレームワーク領域またはヒト化重鎖フレームワーク領域を含む抗体、ならびに
b)ヒトへの投与に好適な薬学的に許容される添加剤;を含み
該個体において、CSFにおけるAβ40および/またはAβ42の量、あるいはニューロンからのAβ40および/またはAβ42の分泌における減少をもたらす、医薬組成物。 - 該抗体が、
(i)配列番号1または配列番号7のアミノ酸配列を含むVL CDR1、
(ii)配列番号2または配列番号8のアミノ酸配列を含むVL CDR2、
(iii)配列番号3または配列番号9のアミノ酸配列を含むVL CDR3、
(iv)配列番号4または配列番号10のアミノ酸配列を含むVH CDR1、
(v)配列番号5または配列番号11のアミノ酸配列を含むVH CDR2、および
(vi)配列番号6または配列番号12のアミノ酸配列を含むVH CDR3
を含む、請求項1または2に医薬組成物。 - 該抗体が、
(i)配列番号7のアミノ酸配列を含むV L CDR1、
(ii)配列番号8のアミノ酸配列を含むV L CDR2、
(iii)配列番号9のアミノ酸配列を含むV L CDR3、
(iv)配列番号10のアミノ酸配列を含むV H CDR1、
(v)配列番号11のアミノ酸配列を含むV H CDR2、および
(vi)配列番号12のアミノ酸配列を含むV H CDR3
を含む、請求項7に記載の医薬組成物。 - 該抗体が、
(i)配列番号1のアミノ酸配列を含むV L CDR1、
(ii)配列番号2のアミノ酸配列を含むV L CDR2、
(iii)配列番号3のアミノ酸配列を含むV L CDR3、
(iv)配列番号4のアミノ酸配列を含むV H CDR1、
(v)配列番号5のアミノ酸配列を含むV H CDR2、および
(vi)配列番号6のアミノ酸配列を含むV H CDR3
を含む、請求項7に記載の医薬組成物。 - 抗体がリポソームに封入されている、請求項1から9のいずれか一項に記載の医薬組成物。
- 抗体が、血液脳関門の通過を促進する薬物と共に製剤されている、請求項1から9のいずれか一項に記載の医薬組成物。
- 抗体が、血液脳関門の通過を促進する担体分子、ペプチドまたはタンパク質に直接またはリンカーを介して融合されている、請求項1から9のいずれか一項に記載の医薬組成物。
- 抗体が、Fv、scFv、Fab、F(ab’)2、またはFab’である、請求項1から9のいずれか一項に記載の医薬組成物。
- タウオパチーを処置する少なくとも1つのさらなる薬物と組み合わせて投与される、請求項1から9のいずれか一項に記載の医薬組成物。
- 静脈内投与される、請求項1から9のいずれか一項に記載の医薬組成物。
- 髄腔内投与される、請求項1から9のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361833355P | 2013-06-10 | 2013-06-10 | |
US61/833,355 | 2013-06-10 | ||
USPCT/US2013/055203 | 2013-08-15 | ||
PCT/US2013/055203 WO2014028777A2 (en) | 2012-08-16 | 2013-08-15 | Methods of treating a tauopathy |
US14/092,539 | 2013-11-27 | ||
US14/092,539 US8926974B2 (en) | 2012-08-16 | 2013-11-27 | Methods of treating a tauopathy |
PCT/US2014/041553 WO2014200921A1 (en) | 2013-06-10 | 2014-06-09 | Methods of treating a tauopathy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016525502A JP2016525502A (ja) | 2016-08-25 |
JP2016525502A5 true JP2016525502A5 (ja) | 2017-06-29 |
JP6446443B2 JP6446443B2 (ja) | 2018-12-26 |
Family
ID=52022687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016519574A Expired - Fee Related JP6446443B2 (ja) | 2013-06-10 | 2014-06-09 | タウオパチーの処置方法 |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP3760228A1 (ja) |
JP (1) | JP6446443B2 (ja) |
CN (1) | CN105339002B (ja) |
BR (1) | BR112015030356A2 (ja) |
CA (2) | CA3173775A1 (ja) |
CY (1) | CY1123672T1 (ja) |
DK (1) | DK3007726T3 (ja) |
EA (1) | EA039554B1 (ja) |
ES (1) | ES2800827T3 (ja) |
HR (1) | HRP20201064T1 (ja) |
HU (1) | HUE050485T2 (ja) |
LT (1) | LT3007726T (ja) |
MX (2) | MX370723B (ja) |
PL (1) | PL3007726T3 (ja) |
PT (1) | PT3007726T (ja) |
RS (1) | RS60883B1 (ja) |
SI (1) | SI3007726T1 (ja) |
WO (1) | WO2014200921A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ730763A (en) | 2012-08-16 | 2018-06-29 | Ipierian Inc | Methods of treating a tauopathy |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
CN107849124B (zh) * | 2015-06-05 | 2021-09-24 | 基因泰克公司 | 抗tau抗体及使用方法 |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
WO2018106781A1 (en) * | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
KR20240035636A (ko) | 2016-12-07 | 2024-03-15 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
MX2019015071A (es) * | 2017-06-16 | 2020-02-13 | Bristol Myers Squibb Co | Composiciones y metodos para tratar tauopatias. |
PE20210115A1 (es) | 2017-10-16 | 2021-01-19 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
WO2020028141A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination therapy |
JP2022043373A (ja) * | 2018-12-28 | 2022-03-16 | 国立大学法人京都大学 | 大脳皮質細胞からのl1cam陽性細胞の取得およびその細胞製剤としての使用 |
US20220177558A1 (en) * | 2019-03-25 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
DK0648271T3 (da) | 1991-08-20 | 2003-07-21 | Us Gov Health & Human Serv | Adenovirusmedieret overførsel af gener til mave-/tarmkanal |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
CA2145641C (en) | 1992-12-03 | 2008-05-27 | Richard J. Gregory | Pseudo-adenovirus vectors |
US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
DE69434486T2 (de) | 1993-06-24 | 2006-07-06 | Advec Inc. | Adenovirus vektoren für gentherapie |
ATE437232T1 (de) | 1993-10-25 | 2009-08-15 | Canji Inc | Rekombinanter adenoviren-vektor und verfahren zur verwendung |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
DE69526377T2 (de) | 1994-12-09 | 2002-11-07 | Microscience Ltd | Virulenzgene in der VGC2-Region von Salmonella |
US5939045A (en) | 1994-12-22 | 1999-08-17 | Nissan Chemical Industries, Ltd. | Organic bismuth derivatives for X-ray imaging |
US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
JP4162267B2 (ja) | 1996-08-27 | 2008-10-08 | カイロン コーポレイション | Neisseria meningitidis血清型B複合糖質およびその使用法 |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
JP2001525470A (ja) | 1997-12-12 | 2001-12-11 | マクロメド・インコーポレーテッド | タンパク修飾のためのヘテロ官能化星形ポリ(エチレングリコール) |
US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
ATE342509T1 (de) | 2000-01-24 | 2006-11-15 | Innogenetics Nv | Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
DK1427709T3 (da) | 2001-09-21 | 2006-04-03 | Mitsubishi Pharma Corp | 3-substituerede 4-pyrimidonderivater |
NZ551335A (en) | 2004-06-18 | 2010-03-26 | Ambrx Inc | Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker |
US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
CN102348723A (zh) | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
US9605054B2 (en) * | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
EP2627672B1 (en) * | 2010-10-11 | 2018-08-01 | Biogen Idec International Neuroscience GmbH | Human anti-tau antibodies |
ES2714692T3 (es) * | 2011-01-31 | 2019-05-29 | Tau Bio Logic Corp | Tratamiento de tauopatías |
GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
NZ730763A (en) * | 2012-08-16 | 2018-06-29 | Ipierian Inc | Methods of treating a tauopathy |
US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
-
2014
- 2014-06-09 PL PL14734364T patent/PL3007726T3/pl unknown
- 2014-06-09 RS RS20200796A patent/RS60883B1/sr unknown
- 2014-06-09 BR BR112015030356A patent/BR112015030356A2/pt active Search and Examination
- 2014-06-09 LT LTEP14734364.4T patent/LT3007726T/lt unknown
- 2014-06-09 PT PT147343644T patent/PT3007726T/pt unknown
- 2014-06-09 WO PCT/US2014/041553 patent/WO2014200921A1/en active Application Filing
- 2014-06-09 DK DK14734364.4T patent/DK3007726T3/da active
- 2014-06-09 EA EA201592203A patent/EA039554B1/ru unknown
- 2014-06-09 SI SI201431606T patent/SI3007726T1/sl unknown
- 2014-06-09 JP JP2016519574A patent/JP6446443B2/ja not_active Expired - Fee Related
- 2014-06-09 EP EP20162335.2A patent/EP3760228A1/en not_active Withdrawn
- 2014-06-09 HU HUE14734364A patent/HUE050485T2/hu unknown
- 2014-06-09 CN CN201480032717.2A patent/CN105339002B/zh not_active Expired - Fee Related
- 2014-06-09 ES ES14734364T patent/ES2800827T3/es active Active
- 2014-06-09 CA CA3173775A patent/CA3173775A1/en active Pending
- 2014-06-09 CA CA2914768A patent/CA2914768A1/en not_active Abandoned
- 2014-06-09 MX MX2015016240A patent/MX370723B/es active IP Right Grant
- 2014-06-09 EP EP14734364.4A patent/EP3007726B1/en active Active
-
2015
- 2015-11-25 MX MX2019015604A patent/MX2019015604A/es unknown
-
2020
- 2020-07-03 CY CY20201100614T patent/CY1123672T1/el unknown
- 2020-07-07 HR HRP20201064TT patent/HRP20201064T1/hr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016525502A5 (ja) | ||
HRP20201064T1 (hr) | Postupci liječenja tauopatije | |
HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
CN110167960B (zh) | 针对金黄色葡萄球菌溶血素a毒素的人类抗体 | |
TWI640537B (zh) | PDGF受體β結合多肽 | |
CA3007000C (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
JP2017530722A5 (ja) | ||
JP2015530971A5 (ja) | ||
JP2016526878A5 (ja) | ||
AR109298A1 (es) | Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso | |
JP2015532592A5 (ja) | ||
JP2018503357A5 (ja) | ||
JP2019527194A5 (ja) | ||
JP2018500014A5 (ja) | ||
WO2015200806A3 (en) | Humanized anti-tau antibodies | |
JP2017523786A5 (ja) | ||
JP2018502840A5 (ja) | ||
JP2016529229A5 (ja) | ||
RU2018135371A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
JP2015533795A5 (ja) | ||
JP2016513664A5 (ja) | ||
JP2011046732A5 (ja) | ||
JP2015503909A5 (ja) | ||
RU2016100892A (ru) | Антитела против tweakr и их применение | |
JP2015504421A5 (ja) |